Next Article in Journal
Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
Next Article in Special Issue
Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1
Previous Article in Journal
Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations
Previous Article in Special Issue
PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
Open AccessReview

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?

1
Department of Pharmacy, Massachusetts General Hospital, Boston, MA 02114, USA
2
Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
3
Harvard Medical School, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(5), 1223; https://doi.org/10.3390/cancers12051223
Received: 7 April 2020 / Revised: 7 May 2020 / Accepted: 11 May 2020 / Published: 13 May 2020
(This article belongs to the Special Issue The Asymptomatic Version of Myeloma: MGUS and Smoldering Myeloma)
The current standard of care for smoldering multiple myeloma (SMM) is observation until there is end-organ involvement. With newer and more effective treatments available, a question that is increasingly asked is whether early intervention in patients with SMM will alter the natural history of their disease. Herein, we review the evolving definition of SMM and risk stratification models. We discuss evidence supporting early intervention for SMM—both as a preventative strategy to delay progression and as an intensive treatment strategy with a goal of potential cure. We highlight ongoing trials and focus on better defining who may require early intervention. View Full-Text
Keywords: smoldering multiple myeloma; early intervention; prognostic features; risk stratification models smoldering multiple myeloma; early intervention; prognostic features; risk stratification models
MDPI and ACS Style

Kim, E.B.; Yee, A.J.; Raje, N. Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? Cancers 2020, 12, 1223.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop